Bio, here's what I don't understand. You seemingly like Blarcamesine but not management. We can agree on that, correct?
What particularly is it about management that you do not like, or are you the type that expects 100% perfection? Because you well know that even the greatest CEOs have made countless blunders. What makes them great CEOs is those blunders never prove fatal to the company or its shareholders.
Anavex has the EMA reviewing Blarcamesine. No debt. A schizophrenia trial with expected readout later this year. $100mm or so in cash. No debt. A world-class scientific advisory board. No debt. Virtually zero competition other than injectables that regulators are wary to approve. Once daily oral pill that potentially lowers blood pressure and improves sleep. No debt.
So yeah, Rett could have been done better but Dr. Missling chose to be compassionate with a trial design that led to a large placebo effect. Anavex has the cash to run another confirmatory trial, or it can focus on Parkinson's. It has options, numerous shots on goal and the cash to make these trials happen.
I just don't see where Dr. Missling has committed a fatal flaw. I've seen lots of competition fall by the wayside but Anavex seems to be in a good position. And every day news comes out from the FDA that leans toward Anavex's favor. The fact Anavex can now get its foot in the door with US Senators is pretty impressive, not something most scam print shops are capable of.
If Anavex pans out, you might make a fortune along with other longs. I hope you do. Sincerely, I want everyone to profit. But that money won't feel the same to you as it will to others because you'll have to accept it knowing your assessment, your conviction, all that was wrong.
AI
Market Data 
Markets 
